STOCK TITAN

Evoke Pharma Inc - EVOK STOCK NEWS

Welcome to our dedicated page for Evoke Pharma news (Ticker: EVOK), a resource for investors and traders seeking the latest updates and insights on Evoke Pharma stock.

Evoke Pharma Inc (EVOK) is a biotechnology innovator focused on advancing treatments for gastrointestinal disorders, notably through its FDA-approved GIMOTI® nasal spray for diabetic gastroparesis. This page provides investors and healthcare professionals with essential updates on the company's strategic initiatives, clinical developments, and market progress.

Access real-time announcements including regulatory milestones, financial results, and partnership agreements that shape Evoke's position in specialty pharmaceuticals. Our curated news feed covers critical updates such as prescription adoption trends, distribution network expansions, and intellectual property developments related to nasal drug delivery technologies.

Key areas of coverage include GIMOTI commercialization progress, pharmacy network partnerships, and operational efficiency initiatives. Bookmark this page to stay informed about Evoke Pharma's advancements in addressing unmet needs in gastrointestinal care through its non-oral therapeutic solutions.

Rhea-AI Summary
Evoke Pharma, Inc. announces the appointment of Matthew J. D’Onofrio as the new CEO, succeeding David A. Gonyer. The company remains focused on GIMOTI® nasal spray for GI diseases. Mr. D’Onofrio expresses commitment to the core mission of expanding GIMOTI's reach to more patients. The board shows confidence in his leadership and vision for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
management
-
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) reported a significant 107% increase in net product sales for fiscal year 2023, totaling $5.2M, with projected net revenue of $14M for 2024. The company focused on expanding market share for GIMOTI nasal spray, resulting in a rise in prescribers, prescription fills, and patient enrollments. Recent developments include reduced healthcare resource utilization with GIMOTI, transition to ASPN Pharmacies for enhanced prescription processes, strengthened patent estate, and improved cash position through a $7.5M public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.15%
Tags
-
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) is set to release its fourth quarter and full year 2023 financial results on March 14, 2024. The company will host a conference call to discuss the results, focusing on their specialty pharmaceutical products for GI diseases, particularly Gimoti® nasal spray.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences earnings
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) closes a $30 million public offering led by Nantahala Capital Management, with potential for an additional $22.5 million if all warrants are exercised. The company plans to use the funds for working capital, general corporate purposes, and potentially for in-licensing, acquiring, or investing in complementary businesses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags
-
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) announced an underwritten public offering led by Nantahala Capital Management, raising up to $30 million for working capital and corporate purposes. The offering includes 11,029,411 shares of common stock and warrants, with a combined price per share of $0.68.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.86%
Tags
-
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) announced that its GIMOTI nasal spray has received a new U.S. patent, No. 11,813,231, listed in the FDA's Orange Book, with coverage until 2029. This adds to the previous three patents, providing enhanced patent protection for GIMOTI. The company aims to redefine gastroparesis treatment with GIMOTI, targeting diabetic gastroparesis and reducing hospitalizations. The patent listing in the Orange Book allows for easier monitoring of potential generic drugs that could infringe on GIMOTI's patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
Rhea-AI Summary
Evoke Pharma, Inc. (NASDAQ: EVOK) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide” for their commercially available and FDA-approved nasal formulation of metoclopramide, GIMOTI. This patent provides additional intellectual property protections and claims to metoclopramide being delivered intranasally. The company sees significant commercial value, especially with the rising popularity of GLP-1 agonist medications for diabetes potentially unmasking gastroparesis in larger patient groups. GIMOTI is the only outpatient, non-oral drug labeled for the treatment of acute and recurrent diabetic gastroparesis, addressing the unpredictability of tablet absorption caused by gastroparesis symptoms. Evoke Pharma aims to continue providing patients with life-changing experiences and enhancing the commercial opportunity for GIMOTI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.2%
Tags
none
-
Rhea-AI Summary
Evoke Pharma, Inc. (NASDAQ: EVOK) reports a 38% revenue increase compared to Q2 2023 and an 88% increase year-over-year. The company experienced a seventh straight prescription fill increase since Q1 2022, with a 21% increase compared to Q2 2023 and a 95% increase year-over-year. The financial results for the third quarter ended September 30, 2023, show record net product sales of $1.6 million. The company also presented data at the ACG 2023 Annual Meeting demonstrating the superiority of its nasal spray, GIMOTI, in reducing healthcare costs for treating diabetic gastroparesis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.34%
Tags
-
Rhea-AI Summary
Evoke Pharma and EVERSANA announced real-world data on the positive impact of GIMOTI nasal spray in reducing healthcare costs for patients with diabetic gastroparesis. Patients and insurers saved over $15,000 per patient in a six-month period by using GIMOTI instead of oral metoclopramide. The study showed a significant reduction in emergency department visits, hospitalizations, and office visits for patients using GIMOTI compared to oral metoclopramide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
Rhea-AI Summary
Evoke Pharma to present real-world healthcare utilization data on GIMOTI nasal spray at the American College of Gastroenterology annual meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
Evoke Pharma Inc

Nasdaq:EVOK

EVOK Rankings

EVOK Stock Data

3.21M
1.41M
5.02%
14.64%
2.1%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SOLANA BEACH